L G Lum
- Activated T-cell and bispecific antibody immunotherapy for high-risk breast cancer. Bench to bedsideL G Lum
Roger Williams Cancer Center, Providence, RI 02908, USA
Acta Haematol 105:130-6. 2001..ATC remain armed, kill tumor targets for days, and produce cytokines after binding to tumor. Arming ATC with BiAbs may prove to be effective for targeting a variety of tumors with and without high-dose chemotherapy...
- Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28-costimulated T cells-phase I clinical trialL G Lum
Cancer Immunotherapy Program, Roger Williams Cancer Center, Providence, Rhode Island, USA
J Immunother 24:408-19. 2001..The detection of cytokines in patient sera and enhanced in vitro production of cytokines by anti-CD3/anti-CD28-stimulated patient PBMCs after COACT infusions suggest that COACTs were modulating immune responses in cancer patients...
- Life or death of T cells with antigen-specific receptors--using T cells for cancer adoptive immunotherapy/gene therapyL Ren-Heidenreich
Immunotherapy Program, Roger Williams Cancer Center, Providence, RI, USA
Curr Gene Ther 1:253-5. 2001..This review discusses the factors that affect the development of AICD or CTL proliferation, and how such factors should be considered in the design of clinical trials using ch-TCR...